Top Chicago, IL Health Tech Companies With Best Stability & Growth (508)

Market Expansion: Headcount and footprint are described as rising to more than 15,000 employees across 40-plus offices, alongside concrete new sites in Hyderabad and a completed Chicago buildout—signals of geographic and capacity expansion. These moves indicate confidence in demand across key delivery hubs.

Innovation-Driven Growth: A dedicated Platforms & Products unit, the ZAIDYN portfolio, and AI-agent initiatives point to sustained investment in productized, AI-enabled offerings. Capability-deepening acquisitions (Digital Additive in 2024 and Torrent Consulting in 2025) further strengthen CRM and multi‑cloud life‑sciences solutions.

Strategic Partnerships: An expanded Salesforce collaboration around Agentforce and recognition as Databricks 2025 Life Sciences Partner of the Year suggest momentum in data/AI ecosystems. These alliances position the firm to capture spend where CRM, data, and AI converge in healthcare and life sciences.

Innovation-Driven Growth: Regulatory momentum is evident with FDA 510(k) clearance for the eVO2peak Module and references to multiple FDA-cleared algorithms, alongside ISO 13485 and MDSAP certifications. Ongoing clinical activity and datasets (e.g., OCORO Heart Study, multi‑million hours of heart data) point to a steadily expanding product and evidence base.

Strategic Partnerships: The March 27, 2025 acquisition by Kardigan integrates Prolaio’s FDA‑cleared software, curated CV datasets, and analytics into a larger R&D platform, signaling added resources and scope. Materials indicate Prolaio continues operating independently while benefiting from Kardigan’s broader heart‑health strategy.

Strong Hiring & Retention: Hiring signals are visible through an active careers page, a stated 32 new hires in 2025, and multiple current openings across functions. Employer recognition such as “Best Places to Work 2026” and ongoing recruiting activity suggest team expansion and brand momentum.

Product Line Growth: Product breadth is expanding with the launch of ALIS 500 benchmarking and the AI assistant “Ask ALIS,” alongside ongoing UX/navigation enhancements in limited release. These moves indicate continued investment in data products and core platform capabilities.

Strategic Partnerships: Partnerships are deepening through new bidirectional integrations such as Inspiren (AI fall detection), Sunbound (payments), and CCN Health (contactless vitals), signaling a growing ecosystem. These additions point to stronger enterprise pull and a more connected operating environment.

Market Expansion: Market presence is rising as the company hosts the ALIS FWD conference and maintains a dense Fall 2026 conference schedule, reflecting stepped‑up marketing and sales activity. Hiring signals and listed openings suggest capacity building to support broader go‑to‑market reach.

Strong Revenue Growth: Revenue expanded rapidly, with FY2025 up 83% to about $1.27B and Q1/Q2 2026 up 36% and 22% year over year, respectively. Management also raised 2026 revenue guidance to approximately $1.595–$1.605B.

Diversified Revenue Streams: Both Diagnostics and Data & Applications are expanding, with Diagnostics up 34.7% in Q1 and 20% in Q2 2026 and Insights/data licensing up 36% in Q2 alongside about $200M in new licenses. Rising oncology test volumes (28–31% YoY) and accelerating MRD tests (~4,700 in Q4 2025 to ~9,000 in Q2 2026) reinforce multiple growth engines.

Profitability: The company achieved its first GAAP-profitable quarter in Q2 2026 (net income about $5.6M; Adjusted EBITDA ~$8.0M). Guidance points to further improvement in 2026, indicating progress toward sustained profitability.

Strategic Partnerships: The acquisition by Model N positions Kalderos’s 340B and gross-to-net capabilities inside a larger life-sciences revenue platform, implying broader distribution and customer access. Integration of the Truzo claims-level visibility into Model N’s suite signals strategic value and scale-up potential.

Strong Revenue Growth: Company materials state revenue more than doubled two years in a row leading into 2023, alongside expanding customers and team. These signals point to strong pre-acquisition traction that can be leveraged under Model N.

Market Expansion: 340B drug purchases reached roughly $66.3B in 2023, indicating a large and expanding market the combined offering serves. This category tailwind supports ongoing demand for discount-management and gross-to-net solutions.

Investor Backing & Capital Strength: Advent International agreed on August 25, 2025 to acquire PatientPoint, with reporting at more than $1.4B, providing external validation and resources to accelerate expansion. This backing is positioned to support network growth and product innovation.

Product Line Growth: In March 2026 PatientPoint launched programmatic buying (Health Audiences) and a Consumer Health Network aimed at CPG/OTC brands, expanding how advertisers can buy and who the company serves. These additions broaden monetization beyond traditional life‑sciences sponsors.

Strong Market Position & Advantage: PatientPoint reports a nationwide footprint in 30,000+ physician offices and 125,000 providers, and in April 2026 received expanded Media Rating Council accreditation across its full digital screen network. This scale and third‑party validation bolster credibility for national buys.

Investor Backing & Capital Strength: Large late-stage financing and valuation momentum signal strong access to capital, including a $250M Series E and corroborated unicorn-scale valuations. Capital depth is further reinforced by indications of continued fundraising interest.

Strategic Partnerships: Embedded distribution with Zillow Rentals’ AI Assist, powered by EliseAI, is reported to drive higher renter engagement and application behavior. Such channel access expands reach and evidences measurable impact in real-world funnels.

Strong Revenue Growth: Company disclosures indicate surpassing $200M in ARR with continued acceleration from earlier milestones. Adoption signals across large operators align with sustained top-line expansion.

Diversified Customer Base: Company materials indicate Strata now serves more than 2,300 organizations across healthcare, higher education, and financial services, with recent moves extending further into financial institutions. The Syntellis combination and the 2026 c. myers acquisition broaden exposure beyond hospitals, diversifying growth drivers.

Product Line Growth: New offerings such as StrataJazz Position Control (June 2025) and AI-driven Predictive Analytics (March 2026) expand the platform’s capabilities. These launches address labor optimization and earlier financial risk detection, signaling continued investment in the product suite.

Strategic Partnerships: A March 2025 collaboration with Snowflake is aimed at handling explosive growth in customer data needs and scaling a large comparable healthcare financial dataset. This alignment supports platform performance and data accessibility as the customer base grows.

Strong Market Position & Advantage: Takeda is consistently placed among the global top 15–20 by revenue and is a clear category leader in GI/IBD, plasma-derived therapies, and dengue vaccines with broad international authorizations and WHO support. Subcutaneous ENTYVIO and new oncology approvals like FRUZAQLA broaden real‑world use and extend reach.

Profitability: Reported FY2025 operating profit rose 19.3% year over year and EPS nearly doubled despite a slight revenue decline, supported by lower amortization and restructuring expense. Core profitability remained broadly stable as Growth & Launch Products expanded their share.

Future-Ready Strategy: Management is investing through FY2026 to convert a late‑stage pipeline (e.g., oveporexton, rusfertide, zasocitinib) into multiple launches, with Growth & Launch Products prioritized as near‑term engines. A multi‑year transformation and efficiency program targeting significant savings by FY2028 is intended to fund launches and strengthen competitiveness.